When Singapore’s telecommunications regulator suspended its review of the proposed merger between Simba Telecom and M1, it did more than delay a single transaction. It sent a clear signal to M&A practitioners worldwide: in an era of heightened regulatory scrutiny, deal certainty is no longer a function of commercial alignment alone. For Keppel Corporation, which had structured a planned $1 billion divestment around the assumption of regulatory clearance, the suspension introduces material uncertainty around valuation, timing, and exit optionality.

This case is not an isolated incident. It reflects a broader pattern reshaping the architecture of cross-border mergers and acquisitions — one that CFOs, General Counsel, and M&A Directors can no longer afford to treat as a back-office compliance issue.

Regulatory Friction Is Now a Structural Feature of Cross-Border M&A

The Singapore situation illustrates a dynamic that has become increasingly common across jurisdictions: sector-specific regulators — particularly in telecommunications, financial services, and critical infrastructure — are asserting review powers that operate independently of, and often in tension with, standard competition authority timelines. The result is a layered approval environment where a transaction may clear antitrust review in one jurisdiction while remaining suspended in another.

This is not unique to Asia-Pacific. In Europe, the EU’s Foreign Subsidies Regulation (FSR), which came into full effect in 2023, has added a third mandatory notification track for transactions involving non-EU state aid. The European Commission’s review of the Lufthansa-ITA Airways deal and the prolonged scrutiny of semiconductor and defense-adjacent acquisitions demonstrate that regulatory friction is now a structural feature of cross-border deals, not an exception.

For deal teams, the practical consequence is a material extension of average time-to-close. According to recent market data, complex cross-border transactions in regulated sectors are now averaging 12 to 18 months from signing to closing — a timeline that compresses IRR for private equity sponsors and introduces significant mark-to-market risk for corporate acquirers.

Strategic Consolidation Continues — But Risk Allocation Is Shifting

Despite regulatory headwinds, deal flow in private markets and mid-cap sectors remains robust. Recent transactions — including Alcon’s agreement to acquire STAAR Surgical, Amphenol’s completed $10.5 billion acquisition of CommScope’s connectivity and cable unit, and York Space Systems’ agreement to acquire Solestial — reflect sustained appetite for strategic consolidation in specialty sectors ranging from medtech to deep-tech supply chains.

What is changing is how risk is being allocated within transaction structures. Boards and their advisors are responding to regulatory uncertainty in several concrete ways:

  • Expanded regulatory conditions precedent: Material Adverse Change (MAC) clauses are being drafted to explicitly capture regulatory suspension events, not merely outright prohibition decisions.
  • Reverse termination fees: Sellers in regulated sectors are demanding higher reverse break fees — in some cases exceeding 5% of enterprise value — to compensate for the optionality cost of exclusivity during extended review periods.
  • Staged closing mechanisms: Particularly in carve-out transactions, parties are structuring interim operating agreements to preserve asset value and business continuity during regulatory limbo.
  • Pre-notification engagement: Sophisticated acquirers are investing in pre-filing dialogue with regulators — a practice standard in EU merger control but increasingly adopted in Asia-Pacific and North American contexts.

Implications for European and Cross-Border Deal Teams

From a European perspective, the Simba-M1 suspension carries direct lessons for transactions involving strategic assets in regulated industries. European General Counsel and M&A Directors should consider the following:

Due diligence must extend beyond competition law. Sector-specific licensing regimes, foreign investment screening mechanisms (including CFIUS in the US and the EU’s FDI screening framework), and national security reviews must be mapped at the outset of any cross-border transaction — not during the regulatory filing phase. Failure to do so creates valuation gaps between signing and closing that are difficult to bridge.

Valuation models must stress-test for regulatory delay. A 12-month extension of the closing timeline on a $1 billion transaction at a 10% cost of capital represents approximately $100 million in time-value erosion. This figure must be reflected in deal economics and, where appropriate, in price adjustment mechanisms.

Post-merger integration planning cannot wait for regulatory clearance. Integration workstreams — particularly those involving IT systems, workforce restructuring, and customer contracts — should be designed in parallel with the regulatory process, with clearly defined trigger points for activation upon clearance.

Key Takeaway

The suspension of the Simba-M1 merger review is a timely reminder that regulatory risk in cross-border M&A is no longer a tail risk — it is a central variable in deal design. For boards and executive teams navigating complex transactions in 2025, the competitive advantage lies not in avoiding regulated sectors, but in building regulatory intelligence, structural flexibility, and scenario-based planning into the deal process from day one. Firms that treat compliance as a transaction cost rather than a strategic input will continue to be surprised. Those that do not, will not.